Analysing the French COVID-19 Epidemic Using a National SARS-CoV-2 RT-PCR Database (CovPCR)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04738331 |
Recruitment Status :
Recruiting
First Posted : February 4, 2021
Last Update Posted : May 26, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Covid-19 SARS-CoV Infection |
Study Type : | Observational |
Estimated Enrollment : | 10000000 participants |
Observational Model: | Other |
Time Perspective: | Retrospective |
Official Title: | Analysing the French COVID-19 Epidemic Using a National SARS-CoV-2 RT-PCR Database : CovPCR |
Actual Study Start Date : | February 1, 2021 |
Estimated Primary Completion Date : | May 20, 2022 |
Estimated Study Completion Date : | June 30, 2022 |

- Detecting co-factors associated with Ct values [ Time Frame: 1 day ]Detecting co-factors associated with Ct values
- Detecting associations with epidemic spread [ Time Frame: 1 day ]Detecting associations with epidemic spread

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion criteria:
- A SARS-Cov2 RT-PCR result with a known sampling date
Exclusion criteria:
- Patient refusing to participate in research

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04738331
Contact: Samuel Alizon, PhD | 610654902 ext 33 | samuel.alizon@cnrs.fr | |
Contact: Vincent Foulongne, PhD | 467 330 254 ext 33 | v-foulongne@chu-montpellier.fr |
France | |
Uh Montpellier | Recruiting |
Montpellier, France, 34295 | |
Contact: Vincent Foulongne, PHD 467 330 254 ext 33 v-foulongne@chu-montpellier.fr |
Study Director: | Vincent Foulongne, PhD | UH MONTPELLIER |
Responsible Party: | University Hospital, Montpellier |
ClinicalTrials.gov Identifier: | NCT04738331 |
Other Study ID Numbers: |
RECHMPL21_0051 |
First Posted: | February 4, 2021 Key Record Dates |
Last Update Posted: | May 26, 2021 |
Last Verified: | May 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Plan Description: | NC |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
SARS-Cov2 infection Tested for SARS-Cov2 infection with RT-PCR test CT epidemiology reproduction number |
Infections COVID-19 Severe Acute Respiratory Syndrome Respiratory Tract Infections Pneumonia, Viral Pneumonia Virus Diseases |
Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases |